research chemical supply retatrutide Retatrutide-RUO 20MG Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

The FDA has approved its use for chronic weight management in adults with a body mass index (BMI) of 30 or more, or a BMI of 27 or more when accompanied by at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes

PNA animals

10.1210/en.2003-1596 145

The FDA hasnt reviewed it

This class of compounds binds to key receptors in the brain, pancreas, and gastrointestinal (GI) tract, instigating several biological reactions: Enhances insulin secretion Slows gastric emptying Increases -cell proliferation Reduces glucagon release Mitigates hunger signaling These actions combine to regulate appetite, food intake, and the physical feeling of fullness (satiety)

But researchers generally agree that the drug harnesses the brains GLP-1 receptors to curb food intake